Oncology Archives - Page 12 of 23

The real-world lifetime economic burden of urothelial carcinoma by stage at diagnosis

Authors: A Aly, C Johnson, Y Doleh, V Chirikov, M Botteman, R Shenolikar, A Hussain Published: Journal of clinical pathways : the foundation of value-based care, 2020 View publication Background Urothelial carcinoma...

The cost of anal cancer in England: retrospective hospital data analysis and Markov model

Authors: S T Keeping, M J Tempest, S J Stephens, S M Carroll, K P Nugent & S T O'Dwyer Published: BMC Public Health, 2014 View publication Background Anal cancer requires a...

Payers’ views on the heterogeneity of treatment effect in oncology

Authors: A Abdalla, D Yoder, F Pradel, D C Mullins Published: The American Journal of Pharmacy Benefits, 2017 View publication Objectives The heterogeneity of treatment effect (HTE) refers to the nonrandom variability...

Phase-specific and lifetime costs of multiple myeloma among older adults in the US

Authors: K Bhattacharya, J P Bentley, S Ramachandran, Y Chang, B F Banahan, R Shah, N Bhakta, Y Yang Published: JAMA Network Open, 2021 View publication Importance Health care costs associated with...

Does biosimilar bevacizumab offer affordable treatment options for cancer patients in the USA? A budget impact analysis from us commercial and Medicare payer perspectives

Authors: J Yang, R Liu, V Ektare, J Stephens, A Shelbaya Published: Applied Health Economics and Health Policy, 2021 View publication Background Bevacizumab remains the most widely used and most thoroughly characterized...

Development of the multiple myeloma symptom and impact questionnaire: a new patient-reported outcome instrument to assess symptom and impacts in patients with multiple myeloma

Authors: K S Gries, J Fastenau, C Seo, B Potrata, C Iaconangelo, D Serrano Published: Value in Health, 2021 View publication Objectives This study aimed to develop and assess the content validity...

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States

Authors: A Chatterjee, S Shapouri, B S Manzoor, A Ravelo, K Sail, V Qendri, G van de Wetering, M S Davids Published: Blood View publication Introduction Historically chemoimmunotherapy has been the standard...

Cost-effectiveness of a 12-month fixed duration of Venetoclax in combination with Obinutuzumab versus chemoimmunotherapy and other novel combinations in first-line chronic lymphocytic leukemia in Canada

Authors: A Chatterjee, G Van de Wetering, R Goeree, A M Desbois, P Manzi, B S Manzoor, C Owen, K Sail Published: Blood, 2021 View publication Objectives To estimate the cost-effectiveness of...

Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States population

Authors: R Shah, S Corman, A Shah, N Kebede, C Nwankwo Published: Journal of Medical Economics, 2021 View publication Aim To estimate the incremental phase-specific and lifetime economic burden among newly diagnosed...

News